Skip to main content
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(1):57–68. doi: 10.1016/j.nurx.2005.12.005

Advances in the treatment of anxiety: Targeting glutamate

Asher B Simon 1,, Jack M Gorman 1
PMCID: PMC3593356  PMID: 16490413

Abstract

Our current psychopharmacological treatments for anxiety disorders evince a number of shortcomings, including troublesome side effects and lack of primary effects. Whereas many new drugs have been developed in the past few decades, most are based on outmoded theories of the pathogenesis of these disorders (i.e., monoamine hypotheses), thus frustrating our ability to create more specific and effective interventions. Recently, however, the neurobiological literature has shown a convergence of findings focusing on the glutamatergic system in anxiety disorders, and the growth of pharmacological tools targeting these receptors has led to the development of novel treatments having anxiolytic effects in humans and animals alike. Additionally, as this system is showing promise as a final common pathway in the pathogenesis of anxiety disorders, we may be able to employ glutamate-specific neuroimaging techniques (e.g., N-acetyl-aspartate, GLX) to both guide treatment decisions and present reliable objective biomarkers for treatment efficacy.

Key Words: Glutamate, anxiety, stress, psychopharmacology, treatment, NMDA antagonist

References

  • 1.MacLean PD. The triune brain in evolution: role in paleocerebral functions. New York: Plenum US; 1990. [DOI] [PubMed] [Google Scholar]
  • 2.LeDoux J. The emotional brain: the mysterious underpinnings of emotional life. New York: Simon & Schuster; 1996. [Google Scholar]
  • 3.Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44:211–218. doi: 10.1001/archpsyc.1987.01800150017003. [DOI] [PubMed] [Google Scholar]
  • 4.Mathew SJ, Mao X, Coplan JD, Smith EL, Sackeim HA, Gorman JM, et al. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004;161:1119–1121. doi: 10.1176/appi.ajp.161.6.1119. [DOI] [PubMed] [Google Scholar]
  • 5.Hollander E, Dell’Osso B. New developments in an evolving field. Psychiatric Times 2005.
  • 6.Germine M. The concept of energy in Freud’s project for a scientific psychology. Ann NY Acad Sci. 1998;843:80–90. doi: 10.1111/j.1749-6632.1998.tb08206.x. [DOI] [PubMed] [Google Scholar]
  • 7.Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ. 2003;326:1008–1008. doi: 10.1136/bmj.326.7397.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord. 1996;41:1–8. doi: 10.1016/0165-0327(96)00050-x. [DOI] [PubMed] [Google Scholar]
  • 9.Rihmer Z. Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry. 2001;16:406–409. doi: 10.1016/s0924-9338(01)00598-3. [DOI] [PubMed] [Google Scholar]
  • 10.Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA. 1998;95:14476–14481. doi: 10.1073/pnas.95.24.14476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Greden JF. Unmet need: what justifies the search for a new antide pressant? J Clin Psychiatry. 2002;63(Suppl 2):3–7. [PubMed] [Google Scholar]
  • 12.Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375:31–40. doi: 10.1016/s0014-2999(99)00330-1. [DOI] [PubMed] [Google Scholar]
  • 13.Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161:1642–1649. doi: 10.1176/appi.ajp.161.9.1642. [DOI] [PubMed] [Google Scholar]
  • 14.Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–198. doi: 10.1001/archpsyc.62.2.190. [DOI] [PubMed] [Google Scholar]
  • 15.Moncrieff J, Wessely S, Hardy R. Active placebos versus anti-depressants for depression. Cochrane Database Syst Rev. 2004;1:CD003012–CD003012. doi: 10.1002/14651858.CD003012.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158:1989–1992. doi: 10.1176/appi.ajp.158.12.1989. [DOI] [PubMed] [Google Scholar]
  • 17.Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray AN, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707–742. doi: 10.1016/s0006-3223(03)00117-3. [DOI] [PubMed] [Google Scholar]
  • 18.Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004;65:1696–1707. doi: 10.4088/jcp.v65n1216. [DOI] [PubMed] [Google Scholar]
  • 19.Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(Suppl 15):42–48. [PubMed] [Google Scholar]
  • 20.Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:67–85. doi: 10.1097/00004714-199902000-00013. [DOI] [PubMed] [Google Scholar]
  • 21.Harris B, Young J, Hughes B. Comparative effects of seven antide pressant regimes on appetite, weight and carbohydrate preference. Br J Psychiatry. 1986;148:590–592. doi: 10.1192/bjp.148.5.590. [DOI] [PubMed] [Google Scholar]
  • 22.Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(Suppl 6):4–6. [PubMed] [Google Scholar]
  • 23.McEwen BS, Olie JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 2005. [DOI] [PubMed]
  • 24.Petrie RX, Reid IC, Stewart CA. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol Ther. 2000;87:11–25. doi: 10.1016/s0163-7258(00)00063-2. [DOI] [PubMed] [Google Scholar]
  • 25.Sanger D, Willner P, Bergman J. Applications of behavioural pharmacology in drug discovery. Behav Pharmacol. 2003;14:363–367. doi: 10.1097/01.fbp.0000092534.95921.34. [DOI] [PubMed] [Google Scholar]
  • 26.Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7(Suppl 1):S71–S80. doi: 10.1038/sj.mp.4001021. [DOI] [PubMed] [Google Scholar]
  • 27.Kendler KS, Karkowski-Shuman L. Stressful life events and genetic liability to major depression: genetic control of exposure to the environment? Psychol Med. 1997;27:539–547. doi: 10.1017/s0033291797004716. [DOI] [PubMed] [Google Scholar]
  • 28.Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA. 2001;98:1912–1917. doi: 10.1073/pnas.041596398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38:213–224. doi: 10.1016/j.npep.2004.05.002. [DOI] [PubMed] [Google Scholar]
  • 30.Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology. 1999;21:52S–60S. doi: 10.1016/S0893-133X(99)00047-0. [DOI] [PubMed] [Google Scholar]
  • 31.Gross C, Hen R. The developmental origins of anxiety. Nat Rev Neurosci. 2004;5:545–552. doi: 10.1038/nrn1429. [DOI] [PubMed] [Google Scholar]
  • 32.Morgan CA, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry. 2002;52:136–142. doi: 10.1016/s0006-3223(02)01319-7. [DOI] [PubMed] [Google Scholar]
  • 33.Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs. 2005;14:601–618. doi: 10.1517/13543784.14.5.601. [DOI] [PubMed] [Google Scholar]
  • 34.McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor α1 subtype. Nat Neurosci. 2000;3:587–592. doi: 10.1038/75761. [DOI] [PubMed] [Google Scholar]
  • 35.Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA. 2000;97:6079–6084. doi: 10.1073/pnas.97.11.6079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Coplan JD, Andrews MW, Rosenblum LA, Owens MJ, Friedman S, Gorman JM, et al. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci USA. 1996;93:1619–1623. doi: 10.1073/pnas.93.4.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cahill L, Prins B, Weber M, McGaugh JL. β-Adrenergic activation and memory for emotional events. Nature. 1994;371:702–704. doi: 10.1038/371702a0. [DOI] [PubMed] [Google Scholar]
  • 38.Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002;51:189–192. doi: 10.1016/s0006-3223(01)01279-3. [DOI] [PubMed] [Google Scholar]
  • 39.Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci. 2003;1003:250–272. doi: 10.1196/annals.1300.016. [DOI] [PubMed] [Google Scholar]
  • 40.Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996;29:23–26. doi: 10.1055/s-2007-979537. [DOI] [PubMed] [Google Scholar]
  • 41.Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. Glutamatehypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders. CNS Spectr. 2001;6:555–564. doi: 10.1017/s1092852900002091. [DOI] [PubMed] [Google Scholar]
  • 42.Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389. doi: 10.1126/science.1083968. [DOI] [PubMed] [Google Scholar]
  • 43.Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8:828–834. doi: 10.1038/nn1463. [DOI] [PubMed] [Google Scholar]
  • 44.Bifulco A, Bernazzani O, Moran PM, Ball C. Lifetime stressors and recurrent depression: preliminary findings of the Adult Life Phase Interview (ALPHI) Soc Psychiatry Psychiatr Epidemiol. 2000;35:264–275. doi: 10.1007/s001270050238. [DOI] [PubMed] [Google Scholar]
  • 45.Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606. doi: 10.1001/archpsyc.1997.01830190015002. [DOI] [PubMed] [Google Scholar]
  • 46.Bagley J, Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience. 1997;77:65–73. doi: 10.1016/s0306-4522(96)00435-6. [DOI] [PubMed] [Google Scholar]
  • 47.McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105–122. doi: 10.1146/annurev.neuro.22.1.105. [DOI] [PubMed] [Google Scholar]
  • 48.Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem. 1993;60:1650–1657. doi: 10.1111/j.1471-4159.1993.tb13387.x. [DOI] [PubMed] [Google Scholar]
  • 49.Moghaddam B, Bolinao ML, Stein-Behrens B, Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res. 1994;655:251–254. doi: 10.1016/0006-8993(94)91622-5. [DOI] [PubMed] [Google Scholar]
  • 50.Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002;51:775–787. doi: 10.1016/s0006-3223(01)01362-2. [DOI] [PubMed] [Google Scholar]
  • 51.Coyle JT, Leski ML, Morrison JH. The diverse roles of L-glutamic acid in brain signal transduction. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Ed 5. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 71–90. [Google Scholar]
  • 52.Bergink V, van Megen HJ, Westenberg HG. Glutamate and anxiety. Eur Neuropsychopharmacol. 2004;14:175–183. doi: 10.1016/S0924-977X(03)00100-7. [DOI] [PubMed] [Google Scholar]
  • 53.Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39. doi: 10.1038/361031a0. [DOI] [PubMed] [Google Scholar]
  • 54.Magarinos AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience. 1995;69:89–98. doi: 10.1016/0306-4522(95)00259-l. [DOI] [PubMed] [Google Scholar]
  • 55.Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci. 2002;5:1039–1042. doi: 10.1038/nn936. [DOI] [PubMed] [Google Scholar]
  • 56.Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA. 1993;90:6591–6595. doi: 10.1073/pnas.90.14.6591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann NY Acad Sci. 2003;1003:292–308. doi: 10.1196/annals.1300.018. [DOI] [PubMed] [Google Scholar]
  • 58.Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry. 2001;6:13–34. doi: 10.1038/sj.mp.4000812. [DOI] [PubMed] [Google Scholar]
  • 59.LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci. 2000;23:155–184. doi: 10.1146/annurev.neuro.23.1.155. [DOI] [PubMed] [Google Scholar]
  • 60.Davis M, Myers KM, Chhatwal J, Ressler KJ. Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx. 2006;3:82–96. doi: 10.1016/j.nurx.2005.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Rogan MT, Staubli UV, LeDoux JE. Fear conditioning induces associative long-term potentiation in the amygdala. Nature. 1997;390:604–607. doi: 10.1038/37601. [DOI] [PubMed] [Google Scholar]
  • 62.Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, fearpotentiated startle, and extinction. Pharmacol Biochem Behav. 2002;71:379–392. doi: 10.1016/s0091-3057(01)00698-0. [DOI] [PubMed] [Google Scholar]
  • 63.Davis M, Rainnie D, Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. 1994;17:208–214. doi: 10.1016/0166-2236(94)90106-6. [DOI] [PubMed] [Google Scholar]
  • 64.Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry. 2001;158:1558–1567. doi: 10.1176/appi.ajp.158.10.1558. [DOI] [PubMed] [Google Scholar]
  • 65.Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a metaanalysis of emotion activation studies in PET and fMRI. Neuroimage. 2002;16:331–348. doi: 10.1006/nimg.2002.1087. [DOI] [PubMed] [Google Scholar]
  • 66.Drevets WC. Neuroimaging abnormalities in the amygdala in mood disorders. Ann NY Acad Sci. 2003;985:420–444. doi: 10.1111/j.1749-6632.2003.tb07098.x. [DOI] [PubMed] [Google Scholar]
  • 67.van den Heuvel OA, Veltman DJ, Groenewegen HJ, Witter MP, Merkelbach J, Cath DC, et al. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry. 2005;62:922–933. doi: 10.1001/archpsyc.62.8.922. [DOI] [PubMed] [Google Scholar]
  • 68.Rauch SL, Shin LM, Wright CI. Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci. 2003;985:389–410. doi: 10.1111/j.1749-6632.2003.tb07096.x. [DOI] [PubMed] [Google Scholar]
  • 69.Rauch SL, Whalen PJ, Shin LM, McInerney SC, Macklin ML, Lasko NB, et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry. 2000;47:769–776. doi: 10.1016/s0006-3223(00)00828-3. [DOI] [PubMed] [Google Scholar]
  • 70.Falls WA, Miserendino MJ, Davis M. Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. JNeurosci. 1992;12:854–863. doi: 10.1523/JNEUROSCI.12-03-00854.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Kim M, McGaugh JL. Effects of intra-amygdala injections of NMDA receptor antagonists on acquisition and retention of inhibitory avoidance. Brain Res. 1992;585:35–48. doi: 10.1016/0006-8993(92)91188-k. [DOI] [PubMed] [Google Scholar]
  • 72.Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature. 1990;345:716–718. doi: 10.1038/345716a0. [DOI] [PubMed] [Google Scholar]
  • 73.Rodrigues SM, Schafe GE, LeDoux JE. Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning. J Neurosci. 2001;21:6889–6896. doi: 10.1523/JNEUROSCI.21-17-06889.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Walker DL, Ressler KJ, Lu KT, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343–2351. doi: 10.1523/JNEUROSCI.22-06-02343.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–1144. doi: 10.1001/archpsyc.61.11.1136. [DOI] [PubMed] [Google Scholar]
  • 76.Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry. 2004;55:1171–1178. doi: 10.1016/j.biopsych.2004.02.029. [DOI] [PubMed] [Google Scholar]
  • 77.N. Burghardt. Insights into panic disorder from fear conditioning models. American College of Neuropsychopharmacology, 43rd Annual Meeting Abstracts, 2004.
  • 78.Boyer PA, Skolnick P, Fossom LH. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci. 1998;10:219–233. doi: 10.1007/BF02761776. [DOI] [PubMed] [Google Scholar]
  • 79.Nowak G, Legutko B, Skolnick P, Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol. 1998;342:367–370. doi: 10.1016/s0014-2999(97)01589-6. [DOI] [PubMed] [Google Scholar]
  • 80.Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther. 1994;269:95–102. [PubMed] [Google Scholar]
  • 81.Watkins CJ, Pei Q, Newberry NR. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res. 1998;61:108–113. doi: 10.1016/s0169-328x(98)00211-3. [DOI] [PubMed] [Google Scholar]
  • 82.Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science. 2004;304:1021–1024. doi: 10.1126/science.1096615. [DOI] [PubMed] [Google Scholar]
  • 83.Berberich S, Punnakkal P, Jensen V, Pawlak V, Seeburg PH, Hvalby O, et al. Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation. J Neurosci. 2005;25:6907–6910. doi: 10.1523/JNEUROSCI.1905-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Yang CH, Huang CC, Hsu KS. Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. J Neurosci. 2005;25:4288–4293. doi: 10.1523/JNEUROSCI.0406-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–77. doi: 10.1038/nature03180. [DOI] [PubMed] [Google Scholar]
  • 86.Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001;58:365–370. doi: 10.1001/archneur.58.3.365. [DOI] [PubMed] [Google Scholar]
  • 87.Nagy J. The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. Curr Drug Targets CNS Neurol Disord. 2004;3:169–179. doi: 10.2174/1568007043337409. [DOI] [PubMed] [Google Scholar]
  • 88.Lopez de Armentia M, Sah P. Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala. J Neurosci. 2003;23:6876–6883. doi: 10.1523/JNEUROSCI.23-17-06876.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Liu XB, Murray KD, Jones EG. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci. 2004;24:8885–8895. doi: 10.1523/JNEUROSCI.2476-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolese Psychiatry. 2000;39:1096–1103. doi: 10.1097/00004583-200009000-00008. [DOI] [PubMed] [Google Scholar]
  • 91.Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci. 2005;25:3270–3279. doi: 10.1523/JNEUROSCI.5033-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression? Neuroscience. 2000;100:681–684. doi: 10.1016/s0306-4522(00)00390-0. [DOI] [PubMed] [Google Scholar]
  • 93.Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. doi: 10.1016/s0006-3223(99)00230-9. [DOI] [PubMed] [Google Scholar]
  • 94.Layer RT, Popik P, Olds T, Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715) Pharmacol Biochem Behav. 1995;52:621–627. doi: 10.1016/0091-3057(95)00155-p. [DOI] [PubMed] [Google Scholar]
  • 95.Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther. 1993;265:1380–1386. [PubMed] [Google Scholar]
  • 96.Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol. 1996;316:145–151. doi: 10.1016/s0014-2999(96)00675-9. [DOI] [PubMed] [Google Scholar]
  • 97.Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1–10. doi: 10.1016/0014-2999(90)90204-j. [DOI] [PubMed] [Google Scholar]
  • 98.Vale S, Espejel MA, Dominguez JC. Amantadine in depression. Lancet. 1971;2:437–437. doi: 10.1016/s0140-6736(71)90153-x. [DOI] [PubMed] [Google Scholar]
  • 99.Xie Z, Commissaris RL. Anxiolytic-like effects of the noncompetitive NMDA antagonist MK 801. Pharmacol Biochem Behav. 1992;43:471–477. doi: 10.1016/0091-3057(92)90178-i. [DOI] [PubMed] [Google Scholar]
  • 100.Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270–276. doi: 10.1001/archpsyc.57.3.270. [DOI] [PubMed] [Google Scholar]
  • 101.Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45:1226–1229. doi: 10.1016/s0006-3223(99)00011-6. [DOI] [PubMed] [Google Scholar]
  • 102.Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63:15–20. doi: 10.4088/jcp.v63n0104. [DOI] [PubMed] [Google Scholar]
  • 103.Sapolsky RM. Glueocortieoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925–935. doi: 10.1001/archpsyc.57.10.925. [DOI] [PubMed] [Google Scholar]
  • 104.Costa E, Silva JA. From restoration of neuroplasticity to the treatment of depression: clinical experience. Eur Neuropsychopharmacol. 2004;14(Suppl 5):S511–S521. doi: 10.1016/j.euroneuro.2004.09.004. [DOI] [PubMed] [Google Scholar]
  • 105.Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al. Stress induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA. 2001;98:12796–12801. doi: 10.1073/pnas.211427898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS. Tianeptine attenuates stressinduced morphological changes in the hippocampus. Eur J Pharmacol. 1992;222:157–162. doi: 10.1016/0014-2999(92)90830-w. [DOI] [PubMed] [Google Scholar]
  • 107.Radley JJ, Sisti HM, Hao J, Rocher AB, McCall T, Hof PR, et al. Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex. Neuroscience. 2004;125:1–6. doi: 10.1016/j.neuroscience.2004.01.006. [DOI] [PubMed] [Google Scholar]
  • 108.Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev. 1992;16:525–534. doi: 10.1016/s0149-7634(05)80194-0. [DOI] [PubMed] [Google Scholar]
  • 109.Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545–553. doi: 10.1001/archpsyc.58.6.545. [DOI] [PubMed] [Google Scholar]
  • 110.Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813–829. doi: 10.1016/s0006-3223(00)01020-9. [DOI] [PubMed] [Google Scholar]
  • 111.Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290–13295. doi: 10.1073/pnas.95.22.13290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098. doi: 10.1016/s0006-3223(99)00041-4. [DOI] [PubMed] [Google Scholar]
  • 113.Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA. 1996;93:3908–3913. doi: 10.1073/pnas.93.9.3908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Cratty MS, Birkle DL. N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. Peptides. 1999;20:93–100. doi: 10.1016/s0196-9781(98)00147-8. [DOI] [PubMed] [Google Scholar]
  • 115.Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry. 2002;7(Suppl 1):S29–S34. doi: 10.1038/sj.mp.4001016. [DOI] [PubMed] [Google Scholar]
  • 116.Carlson PJ, Singh JB, Zarate CA, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx. 2006;3:22–41. doi: 10.1016/j.nurx.2005.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Zinebi F, Xie J, Liu J, Russell RT, Gallagher JP, McKernan MG, et al. NMDA currents and receptor protein are downregulated in the amygdala during maintenance of fear memory. J Neurosci. 2003;23:10283–10291. doi: 10.1523/JNEUROSCI.23-32-10283.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Cottrell JR, Borok E, Horvath TL, Nedivi E. CPG2: a brain- and synapse-specific protein that regulates the endocytosis of glutamate receptors. Neuron. 2004;44:677–690. doi: 10.1016/j.neuron.2004.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Lavezzari G, McCallum J, Dewey CM, Roche KW. Subunit-specific regulation of NMDA receptor endocytosis. J Neurosci. 2004;24:6383–6391. doi: 10.1523/JNEUROSCI.1890-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5:262–269. doi: 10.1038/sj.mp.4000712. [DOI] [PubMed] [Google Scholar]
  • 121.Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7:541–547. doi: 10.1038/87865. [DOI] [PubMed] [Google Scholar]
  • 122.Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res. 2001;43:411–423. doi: 10.1006/phrs.2000.0806. [DOI] [PubMed] [Google Scholar]
  • 123.Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem. 2002;80:589–597. doi: 10.1046/j.0022-3042.2001.00728.x. [DOI] [PubMed] [Google Scholar]
  • 124.Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases N-acetyl-as partate in the human brain: in vivo evidence in support of bcl-2’s neurotrophic effects? Biol Psychiatry. 2000;48:1–8. doi: 10.1016/s0006-3223(00)00252-3. [DOI] [PubMed] [Google Scholar]
  • 125.Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000;356:1241–1242. doi: 10.1016/s0140-6736(00)02793-8. [DOI] [PubMed] [Google Scholar]
  • 126.Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–809. doi: 10.1126/science.1083328. [DOI] [PubMed] [Google Scholar]
  • 127.Zarate CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171–174. doi: 10.1176/appi.ajp.161.1.171. [DOI] [PubMed] [Google Scholar]
  • 128.Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamatemodulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430–432. doi: 10.1016/j.biopsych.2004.11.023. [DOI] [PubMed] [Google Scholar]
  • 129.Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Riluzole in generalized anxiety disorder: an open-label trial. Am J Psychiatry, in press. [DOI] [PubMed]
  • 130.Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003;167:219–220. doi: 10.1007/s00213-003-1396-z. [DOI] [PubMed] [Google Scholar]
  • 131.Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233–S241. doi: 10.1212/wnl.47.6_suppl_4.233s. [DOI] [PubMed] [Google Scholar]
  • 132.Frizzo ME, Dall’Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol. 2004;24:123–128. doi: 10.1023/B:CEMN.0000012717.37839.07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Kniest A, Wiesenberg C, Weber B, Colla M, Heuser I, Deuschle M. The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hyp othalamus-pituitary-adrenocortical system in elderly subjects. Neuropsychobiology. 2001;43:91–95. doi: 10.1159/000054873. [DOI] [PubMed] [Google Scholar]
  • 134.Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in mo derate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341. doi: 10.1056/NEJMoa013128. [DOI] [PubMed] [Google Scholar]
  • 135.Zarate CA Jr, Singh J, Quiroz, JA, Denicoff KD, De Jesus G, Luckenbaugh D, Manji HK, Charney DS. Memantine in major depression: a double-blind placebo-controlled study. Am J Psychiatry, in press. [DOI] [PubMed]
  • 136.Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, et al. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res. 2005;1052:152–162. doi: 10.1016/j.brainres.2005.06.017. [DOI] [PubMed] [Google Scholar]
  • 137.Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov. 2005;4:131–144. doi: 10.1038/nrd1630. [DOI] [PubMed] [Google Scholar]
  • 138.Grillon C, Cordova J, Levine LR, Morgan CA. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003;168:446–454. doi: 10.1007/s00213-003-1444-8. [DOI] [PubMed] [Google Scholar]
  • 139.Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 1996;19:267–271. doi: 10.1016/S0166-2236(96)20019-0. [DOI] [PubMed] [Google Scholar]
  • 140.Palucha A, Pilc A. On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol J Pharmacol. 2002;54:581–586. [PubMed] [Google Scholar]
  • 141.Zarate CA, Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci. 2003;1003:273–291. doi: 10.1196/annals.1300.017. [DOI] [PubMed] [Google Scholar]
  • 142.Koch M. Micro injection s of the metabotropic glutamate receptor agonist, trans-(+/−)-1-amino-cyclopentane-1,3-dicarboxylate (trans-ACPD) into the amygdala increase the acoustic startle response of rats. Brain Res. 1993;629:176–179. doi: 10.1016/0006-8993(93)90500-m. [DOI] [PubMed] [Google Scholar]
  • 143.Rodrigues SM, Bauer EP, Farb CR, Schafe GE, LeDoux JE. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J Neurosci. 2002;22:5219–5229. doi: 10.1523/JNEUROSCI.22-12-05219.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144.Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267–1275. [PubMed] [Google Scholar]
  • 145.Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol. 2001;132:1423–1430. doi: 10.1038/sj.bjp.0703923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethy-nyljpyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology. 2004;29:1971–1979. doi: 10.1038/sj.npp.1300540. [DOI] [PubMed] [Google Scholar]
  • 147.Schulz B, Fendt M, Gasparini F, Lingenhohl K, Kuhn R, Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology. 2001;41:1–7. doi: 10.1016/s0028-3908(01)00036-3. [DOI] [PubMed] [Google Scholar]
  • 148.Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology. 2002;43:181–187. doi: 10.1016/s0028-3908(02)00082-5. [DOI] [PubMed] [Google Scholar]
  • 149.Brodkin J, Busse C, Sukoff SJ, Varney MA. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol Biochem Behav. 2002;73:359–366. doi: 10.1016/s0091-3057(02)00828-6. [DOI] [PubMed] [Google Scholar]
  • 150.Bruno V, Copani A, Knopfel T, Kuhn R, Casabona G, Dell’Albani P, et al. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA induced neuronal degeneration in cultured cortical cells. Neuropharmacology. 1995;34:1089–1098. doi: 10.1016/0028-3908(95)00077-j. [DOI] [PubMed] [Google Scholar]
  • 151.Zahorodna A, Bijak M. An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur J Pharmacol. 1999;386:173–179. doi: 10.1016/s0014-2999(99)00757-8. [DOI] [PubMed] [Google Scholar]
  • 152.Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;75:889–907. doi: 10.1046/j.1471-4159.2000.0750889.x. [DOI] [PubMed] [Google Scholar]
  • 153.Coplan JD, Mathew SJ, Smith EL, Trost RC, Scharf BA, Martinez J, et al. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function. CNS Spectr. 2001;6:607–617. doi: 10.1017/s1092852900002157. [DOI] [PubMed] [Google Scholar]
  • 154.Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology. 2000;39:1139–1146. doi: 10.1016/s0028-3908(99)00215-4. [DOI] [PubMed] [Google Scholar]
  • 155.Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. Anxiolytic and side-effect profile of LY354740: a potent highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 1998;284:651–660. [PubMed] [Google Scholar]
  • 156.Levine LR, Gaydos B, Sheehan DV, Goddard A, Feighner J, Potter WZ, et al. The mGlu2/3 receptor agonist, LY354740, reduces panic anxiety induced by CO2 challenge in patients diagnosed with panic disorder. Neuropharmacology. 2002;43:294–294. [Google Scholar]
  • 157.Melendez RI, Gregory ML, Bardo MT, Kalivas PW. Impoverished rearing environment alters metabotropic glutamate receptor expression and function in the prefrontal cortex. Neuropsychopharmacology. 2004;29:1980–1987. doi: 10.1038/sj.npp.1300507. [DOI] [PubMed] [Google Scholar]
  • 158.Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A, Scaccianoce S, et al. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology. 2002;42:1008–1015. doi: 10.1016/s0028-3908(02)00057-6. [DOI] [PubMed] [Google Scholar]
  • 159.Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349–1352. doi: 10.1126/science.281.5381.1349. [DOI] [PubMed] [Google Scholar]
  • 160.Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci. 2003;17:2409–2417. doi: 10.1046/j.1460-9568.2003.02667.x. [DOI] [PubMed] [Google Scholar]
  • 161.Linden AM, Johnson BG, Peters SC, Shannon HE, Tian M, Wang Y, et al. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology. 2002;43:251–259. doi: 10.1016/s0028-3908(02)00079-5. [DOI] [PubMed] [Google Scholar]
  • 162.Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx. 2006;3:117–130. doi: 10.1016/j.nurx.2005.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Coyle JT. The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis. 1997;4:231–238. doi: 10.1006/nbdi.1997.0153. [DOI] [PubMed] [Google Scholar]
  • 164.Lyoo IK, Renshaw PF. Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry. 2002;51:195–207. doi: 10.1016/s0006-3223(01)01313-0. [DOI] [PubMed] [Google Scholar]
  • 165.Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem. 2000;74:254–262. doi: 10.1046/j.1471-4159.2000.0740254.x. [DOI] [PubMed] [Google Scholar]
  • 166.Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology. 1999;53:806–812. doi: 10.1212/wnl.53.4.806. [DOI] [PubMed] [Google Scholar]
  • 167.Kantarci K, Jack CR. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003;13:197–209. doi: 10.1016/s1052-5149(03)00025-x. [DOI] [PubMed] [Google Scholar]
  • 168.Sacktor N, Skolasky RL, Ernst T, Mao X, Seines O, Pomper MG, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging. 2005;21:325–333. doi: 10.1002/jmri.20272. [DOI] [PubMed] [Google Scholar]
  • 169.Kegeles LS, Humaran TJ, Mann JJ. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol Psychiatry. 1998;44:382–398. doi: 10.1016/s0006-3223(97)00425-3. [DOI] [PubMed] [Google Scholar]
  • 170.Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 2000;47:305–313. doi: 10.1016/s0006-3223(99)00159-6. [DOI] [PubMed] [Google Scholar]
  • 171.Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN, et al. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:595–606. doi: 10.1001/archpsyc.1996.01830070041008. [DOI] [PubMed] [Google Scholar]
  • 172.Dager SR, Marro KI, Richards TL, Metzger GD. Preliminary application of magnetic resonance spectroscopy to investigate lactate-induced panic. Am J Psychiatry. 1994;151:57–63. doi: 10.1176/ajp.151.1.57. [DOI] [PubMed] [Google Scholar]
  • 173.Phan KL, Fitzgerald DA, Cortese BM, Seraji-Bozorgzad N, Tancer ME, Moore GJ. Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport. 2005;16:183–186. doi: 10.1097/00001756-200502080-00024. [DOI] [PubMed] [Google Scholar]
  • 174.Kegeles LS, Shungu DC, Anjilvel S, Chan S, Ellis SP, Xanthopoulos E, et al. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 2000;98:163–175. doi: 10.1016/s0925-4927(00)00044-5. [DOI] [PubMed] [Google Scholar]
  • 175.Mathew SJ, Shungu DC, Mao X, Smith EL, Perera GM, Kegeles LS, et al. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry. 2003;54:727–735. doi: 10.1016/s0006-3223(03)00004-0. [DOI] [PubMed] [Google Scholar]
  • 176.Harte MK, Powell SB, Reynolds LM, Swerdlow NR, Geyer MA, Reynolds GP. Reduced N-acetyl-aspartate in the temporal cortex of rats reared in isolation. Biol Psychiatry. 2004;56:296–299. doi: 10.1016/j.biopsych.2004.06.009. [DOI] [PubMed] [Google Scholar]
  • 177.Block W, Bayer TA, Tepest R, Traber F, Rietschel M, Muller DJ, et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett. 2000;289:147–151. doi: 10.1016/s0304-3940(00)01264-7. [DOI] [PubMed] [Google Scholar]
  • 178.Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res. 2005;73:153–157. doi: 10.1016/j.schres.2004.08.021. [DOI] [PubMed] [Google Scholar]
  • 179.Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556–561. doi: 10.1001/archpsyc.58.6.556. [DOI] [PubMed] [Google Scholar]
  • 180.Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, et al. Reduced cortical γ-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999;56:1043–1047. doi: 10.1001/archpsyc.56.11.1043. [DOI] [PubMed] [Google Scholar]
  • 181.Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. Subtype specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705–713. doi: 10.1001/archpsyc.61.7.705. [DOI] [PubMed] [Google Scholar]
  • 182.Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, α-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab. 1995;15:12–25. doi: 10.1038/jcbfm.1995.2. [DOI] [PubMed] [Google Scholar]
  • 183.Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci USA. 1999;96:8235–8240. doi: 10.1073/pnas.96.14.8235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184.Boyce S, Wyatt A, Webb JK, O’Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology. 1999;38:611–623. doi: 10.1016/s0028-3908(98)00218-4. [DOI] [PubMed] [Google Scholar]
  • 185.Chizh BA. Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article. Amino Acids. 2002;23:169–176. doi: 10.1007/s00726-001-0124-4. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES